# Yoshihiko Tomita

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yoshihiko-tomita/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,438 |
| Field | Renal cell carcinoma treatment |
| h-index | 56 |
| i10-index | 187 |
| Last Known Institution | Niigata University Medical and Dental Hospital |
| OpenAlex ID | https://openalex.org/A5007596741 |
| ORCID iD | https://orcid.org/0000-0002-7465-9591 |
| Works | 472 |

## Researcher papers

- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients](https://scholariq.org/papers/prognosis-of-japanese-metastatic-renal-cell-carcinoma-patients-in-the-cytokine/)
- [Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-in-patients-with/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)

## Researcher university

- [Niigata University Medical and Dental Hospital](https://scholariq.org/institutions/niigata-university-medical-and-dental-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.